Skip Navigation

Annals of Oncology 2006 17(Supplement 5):v33-v36; doi:10.1093/annonc/mdj947
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Abratt, R. P.
Right arrow Articles by Hart, G. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abratt, R. P.
Right arrow Articles by Hart, G. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

symposium article

10-year update on chemotherapy for non-small cell lung cancer

R. P. Abratt and G. J. Hart

Division of Radiation Oncology, Department of Radiation Medicine, Groote Schuur Hospital & University of Cape Town, South Africa

Correspondence to: Prof. R. P. Abratt, Radiation Oncology, Department of Radiation Medicine, Groote Schuur Hospital, Observatory 7925, Cape Town, South Africa. Tel: +27-21-4044265; Fax: +27-21-4045259; E-mail: rpa{at}curie.uct.ac.za

Background: A 1995 meta analysis of chemotherapy in patients with advanced non-small cell carcinoma indicated clinical benefit from cisplatin based chemotherapy. Subsequent studies have aimed to increase the efficacy or decrease the toxicity of chemotherapy.

Patient and methods: Illustrative studies and meta analyses of different aspects of chemotherapy which have taken place over the last decade, are reviewed.

Results: The use of novel (third generation) chemotherapy agents has resulted in a further increase in patient survival. Gemcitabine was shown to be associated with an increase in progression free survival when compared to other third generation agents as well as a strong tendency to increased overall survival. An increase in survival was also shown with doublet chemotherapy regimes as compared to the use of single agents only. The use of triplet agent chemotherapy results in no further increased survival, but increased toxicity. Cisplatin is associated with increased survival over carboplatin based chemotherapy regimens when third generation agents are used, but increased nausea and vomiting. Non-platin third generation combinations give equivalent survival to platin-based regimens.

Conclusions: First line chemotherapy given to patients with advanced NSCLC should be two-drug combination regimen. Non-platin containing regimens may be used as an alternative to platinum based regimens in the first line.

Key words: chemotherapy, non-small cell lung cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
S. R. McWhinney, R. M. Goldberg, and H. L. McLeod
Platinum neurotoxicity pharmacogenetics
Mol. Cancer Ther., January 1, 2009; 8(1): 10 - 16.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.